New research report provides overview of generic drug market in Japan

Published on August 19, 2014 at 1:13 AM · No Comments

Research and Markets has announced the addition of the "The Overveiw of Japanese Generic Drug Market" report to their offering.

This report talks about the overview of Japanese generic drug market. It gives the readers ann understanding of the overall climate surrounding generic market in Japan.

The report covers related regulations, generics's share in Japan, market size, primary makers, market trend, and updated situation about biosimilars and authorized generics.

The share of generics in the prescription drugs market increased in terms of both volume and value. The 2012 volume share was 25.8%. This increase has been particularly pronounced since 2007 due to government measures devised to increase the use of generics.

The market size for generics in 2012 was about 55 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 78 billion JPY in 2016.

Physicians in Japan who possess the ability to write prescriptions hold a deeply rooted faith in new drugs. Moreover, as it benefits medical institutions and pharmacies to give preferential treatment to new drugs that conventionally have large profit margins, the use of generics has not increased much.

Key Topics Covered:

  1. Summary
  2. Definition of Generic Drugs
  3. Laws and Regulations Pertaining to Generics
  4. NHI Drug Price
  5. Share of Generics in Prescription Drugs Market
  6. Market Size
  7. Sales of Leading Japanese Companies
  8. Principal Industry Association
  9. Primary Generic Manufacturers
  10. Overview of Leading Japanese Generics Companies
  11. Current Market Environment Conditions
  12. Considerations by Company Type
  13. Government Measures to Promote the Use of Generics
  14. Biosimilars
  15. Authorized Generics
  16. Future Outlook

Companies Mentioned:

  • Actavis
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Hospira
  • Lupin
  • Meiji
  • Mochida
  • Mylan
  • Nichi-Iko
  • Nippon Chemiphar
  • Nippon Kayaku,Kissei
  • Ohara
  • Sandoz
  • Sanwa
  • Sawai
  • Teva
  • Towa
  • Zydus

Research and Markets

Posted in: Pharmaceutical News

Tags: ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals